Given the ethnic difference of HLA-I supertypes between Chinese versus Western populations17 and without HLA-I genotyping data in TCGA (The Cancer Genome Atlas) or ICGC (International Cancer Genome Consortium), co-mutant KRAS G12D and TP53 correlated with HLA-A02+B62+B44− was used as a derived genomic ‘indicator’ to test the prognostic significance of HLA-A02+B62+B44− for PAAD in public data. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.